August 26 | 2021 2cureX publishes interim report for the second quarter and first half of 2021 Read more
August 20 | 2021 New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer. Read more
July 29 | 2021 2cureX appoints two internationally highly recognized oncologists as Clinical Advisors Read more
July 1 | 2021 2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer Read more
June 7 | 2021 ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients Read more
June 1 | 2021 Management exercise all warrants within the framework of the 2018 incentive program Read more
May 20 | 2021 2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting Read more
May 11 | 2021 Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK Read more
May 11 | 2021 Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million. Read more